Background: Hyperlipidemia is a known risk factor for cardiovascular disease.
Statins therapy greatly reduce the risk of cardiovascular events. The rationale
of this study was to investigate the effectiveness of Atorvastatin (20mg vs.
40mg) in lowering LDL-C levels.
Aim: To determine
the effectiveness of Atorvastatin (Low vs. High Dose) in terms of lowering LDL
to < 100mg/dl in patients with Intermediate risk of cardiovascular disease
by Framingham risk score.
Methodology: It was a randomized controlled trial and 140 patients, previously on no
lipid lowering therapy, were divided into two groups by lottery method. This
study was completed in 6 months after it was approved from IRB/ASRB.Baseline
LDL cholesterol levels were recorded. One group was given low dose (20mg) atorvastatin
while other was given high dose (40mg) atorvastatin for 6 months. LDL levels
were again monitored after 6 months and efficacy of treatment was assessed.
mean age of the patients in group 1 was 61.67 years (SD 9.84) and group 2 was
66.7 years (SD 8.78), mean LDL-C levels were 149.24 mg/dl (SD 27.767). In group
1, 62.9% were males and 37.1% were females, whereas in group 2, 65.7% were
males and 34.3% were females. Family history of cardiovascular disease was
present in 61% of the patients, 41.43% were smokers, 59.3% were hypertensive
and 45% were Diabetic. Chi square test revealed that both therapies had
significant effect on lowering LDL-cholesterol and were equally effective.
Conclusion: Low dose Atorvastatin to reduce the LDL-C levels in Intermediate risk
patients is equally effective and can help to get the same benefit from low
dose preventing the side effects of high dose.
Key words: Cardiovascular
disease, low density lipoprotein cholesterol, atorvastatin